Publications by authors named "W Wilcox"

Claim this Profile
H
Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.
Dominique P Germain, Pronabesh DasMahapatra, Shiguang Liu, Patrick Deegan, Alberto Ortiz, William R Wilcox

Mol Genet Genomic Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Decision Support Aiming to Accelerate Triage and Time to Dextrose-Containing IV Fluids in the ED for Children with Severe Metabolic Conditions.
Swaminathan Kandaswamy, Shabnam Jain, Dwight Diaz Chambers, William R Wilcox, Beesan S Agha

Appl Clin Inform· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Content Analysis of Maternal Toxicology Testing Policies to Inform Equity in Substance Use Disorder Identification.
Leah L Habersham, Sugy Choi, Michelle Gelband, Wendy Wilcox, Angela Bianco

Matern Child Health J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
Ravi Savarirayan, Melita Irving, William R Wilcox, Carlos A Bacino, Julie E Hoover-Fong

Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension.
Uma Ramaswami, Esperanza Font-Montgomery, Ozlem Goker-Alpan, Damara Ortiz, Amarilis Sanchez-Valle, William R Wilcox

Mol Genet Metab· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis